Tag: molnupiravir
-
This is Why Pfizer Just Popped, As We Expected
Pfizer is pushing to higher highs. In fact, as we noted on November 2, “After finding support around $41, the vaccine stock bolted to nearly $46, and could test $47, even $50, near-term. All after the company raised its full-year sales forecast to $36 billion, as it signed deals for booster doses. The stock could…